WHO preferred product characteristics for new vaccines against tuberculosis

Lancet Infect Dis. 2018 Aug;18(8):828-829. doi: 10.1016/S1473-3099(18)30421-3.

Authors

Lewis K Schrager¹, Padmapriyadarsini Chandrasekaran², Bernard H Fritzell³, Mark Hatherill⁴, Paul-Henri Lambert⁵, Helen McShane⁶, Nadia Tornieporth⁶, Johan Vekemans⁷

Affiliations

¹ WHO Initiative for Vaccine Research. Geneva, Switzerland.
² National Institute of Research in Tuberculosis, India.
³ Tuberculosis Vaccine Initiative, Netherlands.
⁴ South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa.
⁵ University of Geneva, Geneva, Switzerland.
⁶ Hannover University of Applied Science and Arts, Hannover, Germany.
⁷ WHO, Geneva, Switzerland. Electronic address: johan.vekemans@gmail.com.

PMID: 30064668
DOI: 10.1016/S1473-3099(18)30421-3

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic* / administration & dosage
Adolescent
Adult
Animals
BCG Vaccine* / administration & dosage
BCG Vaccine* / pharmacology
Developing Countries
Drug Design*
Global Health
Humans
Infant
Infant, Newborn
Mycobacterium tuberculosis / isolation & purification
Research
Tuberculosis / epidemiology
Tuberculosis / prevention & control*
Vaccination / standards*
Vaccination / trends

Substances

Adjuvants, Immunologic
BCG Vaccine

Grants and funding

001/WHO_/World Health Organization/International